Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2004

View Archived Issues

Activity of fidarestat in diabetic neuropathy evaluated in mice and humans

Schering AG names new derma company Intendis

Bonefos accepted for priority review

Oscient launches Factive for lower respiratory tract infections

Roche and Structural GenomiX form antiviral alliance

New FAAH inhibitors and their use in pain and other disorders

Aventis presents novel PTP inhibitors and their use

Novel GPa inhibitors prepared and tested by Aventis researchers

New gamma-secretase inhibitors designed by Sanofi-Synthelabo team

Pfizer claims new 5-HT7 receptor modulators for depression, anxiety, etc.

New alpha2, alpha3 and/or alpha5-selective GABA-A receptor ligands claimed by Merck

Novel 11beta-HSD-1 inhibitors in early development at Novartis

New PYY analogues and their use in body weight disorders

Promising p38alpha inhibitor against the progression of rheumatoid arthritis

Orally active PDE4 inhibitor for the treatment of inflammatory respiratory diseases

Antiobesity treatment with melanin-concentrating hormone receptor-1 antagonist

Enrollment completed in phase III anidulafungin study

Multikine lowers cholesterol in clinical studies

H3 Pharma and DSM sign manufacturing agreement for SC-1

New dosage strengths of Avandamet approved in E.U.

IR-103 enters first clinical testing

Positive phase IIb results for harkoseride in epilepsy

Vivus initiates phase III study of Alista

Eurand to develop modified-release lercanidipine for Recordati

TheraQuest Biosciences discovers analgesic synergy with narcotics

Strakan and ProSkelia complete merger, renamed ProStrakan

Rivastigmine reported to slow cognitive decline in AD regardless of disease severity

Clinical trials assess the effects of magnesium sulfate in asthma and COPD

Tobacco smoke and immunosuppression in lung transplantation

Coating medical devices with key protein to prevent infection

FDA advisory committee recommends further data for Exanta approval

Aminoguanidine, ALT-711 renoprotective in hyperlipidemia/diabetes model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...